Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces That Data From Multiple Studies Demonstrate “Real-World” Value of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 19, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced that early user-experience data from three independent studies demonstrate that the next-generation Afirma Genomic Sequencing Classifier (GSC) significantly increases the number of patients who can
Toggle Summary Veracyte Launches Early Access Program for Envisia Genomic Classifier to Improve Diagnosis of IPF
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 17, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it has launched an Early Access Program to begin making the Envisia Genomic Classifier available to patients being evaluated for interstitial lung diseases (ILD), including idiopathic


Date Event Details
Summary Toggle Sep 8, 2016 11:00 AM EDT
Veracyte Percepta Medicare Coverage Conference Call
Summary Toggle Nov 29, 2016 3:30 PM EST
Piper Jaffray 28th Annual Healthcare Conference


Title Documents

Veracyte Corporate Presentation, May 2018